drugset / Trial / NCT00346385
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed or refractory solid tumors.
Timeline
- Start
- 2002-03
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorvotuzumab Mertansine | Monoclonal antibody | — | Intravenous |